Sino Biopharmaceutical to acquire LaNova Medicines for up to $951 million
15/07/2025 12:00
July 15 (Reuters) - Hong Kong-listed Sino Biopharmaceutical 1177.HK said on Tuesday it will buy the remaining 95.09% stake it does not hold in Shanghai-based LaNova Medicines for no more than $950.92 million. (Reporting by Shivangi Lahiri in Bengaluru; Editing by Mrigank Dhaniwala) ((Shivangi.Lahiri@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsBrief: Sino Biopharmaceutical Announces Share Purchase Plan For HK$2 Billion
Brief: Sino Biopharmaceutical Says Marketing Application For M701 Accepted By China In May 2026
Brief: Sino Biopharmaceutical Says Zongertinib Approved By NMPA China
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment (updated)
HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up